FibroBiologics to Present at JonesTrading Healthcare Summit 2024

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation in the JonesTrading Healthcare Seaside Summit on July 15, 2024, in San Diego. Founder and CEO Pete O'Heeron will present at 1:45 p.m. PDT. The presentation will be accessible via webcast, with replay links available on the company's Investor Relations page.

FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company holds over 150 patents issued and pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. Based in Houston, FibroBiologics represents the next generation of medical advancement in cell therapy.

HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the JonesTrading Healthcare Seaside Summit occurring July 14-16, 2024, in San Diego, California.

Details of the presentations are as follows:

Presentation Date: Monday, July 15, 2024
Time: 1:45 p.m. PDT
Webcast Registration: https://wsw.com/webcast/jones/fblg/1793925

Links to the replay will be accessible under the “News & Events” tab on the Investor Relations page on the company’s website at  https://ir.fibrobiologics.com/news-events/ir-calendar.

For more information, please visit FibroBiologics' website or email FibroBiologics at info@fibrobiologics.com.

About FibroBiologics

Based in Houston, FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

When and where is FibroBiologics (FBLG) presenting at the JonesTrading Healthcare Summit 2024?

FibroBiologics (FBLG) is presenting on Monday, July 15, 2024, at 1:45 p.m. PDT at the JonesTrading Healthcare Seaside Summit in San Diego, California.

How can investors access FibroBiologics' (FBLG) presentation at the JonesTrading Healthcare Summit?

Investors can access the presentation via webcast at https://wsw.com/webcast/jones/fblg/1793925. Replay links will be available on the Investor Relations page of FibroBiologics' website.

What is FibroBiologics' (FBLG) main focus in biotechnology?

FibroBiologics (FBLG) focuses on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials.

How many patents does FibroBiologics (FBLG) hold as of July 2024?

As of July 2024, FibroBiologics (FBLG) holds over 150 US and internationally issued patents and patents pending across various clinical pathways.

What are some of the clinical areas FibroBiologics (FBLG) is working on?

FibroBiologics (FBLG) is working on clinical pathways including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer.